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Abstract
Wei–Lin–Weissfeld (WLW) method is used to analyze different states of the superficial vesical carcinoma distinguishing
between recurrences and the possibility of progression. Two approaches are considered in this analysis to represent different
aspects of the disease from a clinical point of view: the first one attempts to focus on the effect of the clinico-pathological factors
on recurrences by regarding a progression before the recurrence as a censoring event, meanwhile the second one analyzes these
same effects on either recurrence or progression, whichever comes first. A predictive model of recurrence or progression based on
clinico-pathological factors is presented.
c© 2008 Elsevier Ltd. All rights reserved.
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1. Introduction
Bladder carcinoma is a highly aggressive neoplasm and the second most common malignancy encountered by
urologists. It is the fourth most frequent solid tumor among men and the seventh most frequent among women, with
more than 350 000 new cases diagnosed annually worldwide [1]. Fortunately, approximately 80% of patients with
newly diagnosed bladder carcinoma present superficial transitional cell carcinoma (TCC), which can be managed
with transurethral resection (TUR) [2]. However, more than 50% of the patients will have recurrences (reappearance
of a superficial tumor) and 10%–30% of the patients will have progression to muscle invasive disease [3].
There are many advantages in establishing the risk factors associated with the recurrence and progression of bladder
cancer and in creating a model that allows the prediction of the disease process after the TUR. Firstly, this will provide
information to the physician about the patient’s recurrence–progression process that allows him to program in a more
rigorous way the follow-up of the patient. As a consequence, we accomplish a major objective: that of reducing the
number of painful check tests on the patients with lower risk. Furthermore, it allows us to reduce the programming-
visit, and to prioritize and pay more attention to the cases that need it. In that way, both time and sanitary expenses
are minimized.
A number of studies have been performed to identify prognostic factors for the first recurrence of superficial TCC
in the bladder cancer after TUR and an initial treatment [4–8]. However very few studies [9] have systematically
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investigated the multiple recurrences of this cancer (the main characteristic of superficial TCC of the bladder) and its
associated factors as well as the progression. So we would be interested in the analysis of associated factors of the risk
of a new recurrence or a progression in the multiple events of bladder carcinoma with the aim of creating a predictive
model of this disease process. Besides, from a medical point of view a deeper knowledge of the process can help to
better understand the disease’s course and thus arrive at a better treatment adjust.
For the analysis of time to the first event the Cox proportional model has mostly been used [11] with the associated
partial likelihood principle [12]. In the last few years several methods have been proposed to analyze recurrent events.
Three extensions of the Cox model have become popular: the Andersen and Gill (AG) [13], the Prentice, Williams
and Peterson (PWP) [14] and the Wei, Lin and Weissfeld (WLW) [15] (see [16] for a performance of these models and
their applications). In [17] a review of methods for recurrent events is shown and the same authors have just published
a book on the topic [18].
Several authors have used the WLW method to study processes with a recurring and a terminating event [19–21].
The terminating event could be any event of essential interest which precludes further observation of the process. In
our case the recurring event is the reappearance of the TCC tumor and the terminating event is the progression because
this leads to a more aggressive treatment, including bladder extirpation. The WLW method has been deeply studied,
see [22] for a recent contribution.
The paper is organized as follows: in Section 2 we review the WLW method and two different approaches to
analyze the recurrence–progression process are considered. In Section 3 we apply the WLW method to our bladder
cancer database to study the predictive factors of recurrence and progression and estimate the risk of both events. We
validate the model and finally in Section 4 the most relevant conclusions are presented.
2. The WLWmethod and the recurrence–progression process
2.1. The WLW method
Let T be the first event time. The hazard function expresses the risk or hazard of the event at some time t , and is
defined by [10]
λ(t) = lim
h→0
P(t ≤ T < t + h | T ≥ t)
h
.
The hazard function of the proportional hazard model [11] is
λ(t) = eβ ′Z(t)λ0(t), (1)
where β is a p × 1 vector of unknown regression parameters, λ0(t) is an unspecified baseline hazard function and
Z = (Z1, . . . , Z p)′ is a p × 1 vector of possibly time-varying covariates. Let C denote the time from the study entry
until the end of the study. This is the censoring time. We can determine X = min(T, C) and ∆ = I (T ≤ C), where
I () is the indicator function. So if∆ = 1 the event occurs, and if∆ = 0 we say that the observation is right-censored.
Assume that T and C are independent conditional on Z . Let (X i , ∆i , Zi ) for each patient (i = 1, . . . , n). Then the
partial likelihood function [12] for β is
L(β) =
n∏
i=1

eβ
′Zi (X i )
n∑
j=1
Y j (X i )eβ
′Z j (X i )

∆i
, (2)
where Y j (t) = I (X j ≥ t). This function is not strictly a likelihood, but it can be treated as a likelihood for purposes
of asymptotic inference [12]. The corresponding score function ∂ log L(β)
∂β
is
U (β) =
n∑
i=1
∆i
Zi (X i )−
n∑
j=1
Y j (t)eβ
′Z j (t)Z j (t)
n∑
j=1
Y j (t)eβ
′Z j (t)
 . (3)
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Fig. 1. Recurrence–progression process.
The maximum partial likelihood estimator βˆ is the solution to {U (β) = 0}. For large n, the score statistic U (βˆ)
is approximately p-variate normal with mean 0 and with estimated covariance matrix A(βˆ), and βˆ is approximately
p-variate normal with mean β and with estimated covariance matrix A−1(βˆ), where A(β) = − ∂2 log L(β)
∂β2
.
Let us now suppose that each patient may experience K events. The WLW method consists in formulating a
Cox model for each event. So, let Tik be the time when the kth event occurs on the i th patient, and let Cik be the
corresponding censoring time. Define X ik = min(Tik, Cik). And let∆ik = I (Tik ≤ Cik). The hazard function of the
i th patient for the kth event is
λk(t; Zik) = λ0k(t)eβ ′Zik (t), (4)
where λ0k(t) (k = 1, . . . , K ) are unspecified baseline hazard functions for each recurrence, β = (β1, . . . , βp)′ is a
p × 1 vector of unknown regression parameters and Zik denotes the covariate vector for the i th patient with respect
to the kth event. β is allowed to be different for each event. Then the partial likelihood function for β is written as
follows
L(β) =
n∏
i=1
K∏
k=1

eβ
′Zik (X ik )
n∑
j=1
Y jk(X ik)eβ
′Z jk (X i k)

∆ik
, (5)
where Yik(t) = I (X ik ≥ t).
2.2. The robust variance
The Cox model estimate of variance for βˆ treats each of the observations as independent. As observations are
generally correlated within the same patient the derivative matrix A(βˆ) does not provide a valid variance–covariance
matrix estimator [23,21,15]. In this sense [24] proposes a correction of the variance–covariance matrix (robust
variance–covariance estimate) by means of a sandwich estimator. In [15] this robust variance is studied in the context
of multiple events. The computation of corrected variance is not difficult in the framework presented in [16].
2.3. The recurrence–progression process
Starting from the TUR, a patient is observed during a follow-up period where several events may occur. Each patient
can undergo one or more recurrences (recurring events) that can be interrupted by the occurrence of the progression
(terminating event) or suffering a progression after TUR. The process is depicted in Fig. 1. In our analysis we have
considered up to a maximum of 3 recurrences per patient. In that case a patient can experience up to 4 events (three
recurrences followed of a progression). Those patients who have experienced neither recurrence nor progression are
censored, that is, the event of interest has not been observed in the whole period of follow-up for those individuals.
We have considered two different approaches to illustrate the two outcomes of interest (a new recurrence or a
progression) of our data in Fig. 1. These two approaches represent different paths of the recurrence–progression
process [19] that we are interested in analyzing. So, this will let us carry out several inferences on the two outcomes.
Table 1 shows both approaches with all possible paths in the recurrence–progression process.
Approach I defines the first three events for a patient as her/his first, second, and third recurrences respectively, and
the fourth event as progression. This approach defines four strata or levels for studying: time to the first recurrence
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Table 1
The two approaches
Observation APPROACH I APPROACH II
k = 1 k = 2 k = 3 k = 4 k = 1 k = 2 k = 3 k = 4
R1R2R3P R1 R2 R3 P R1 R2 R3 P
R1R2P R1 R2 P
+ P R1 R2 P P
R1P R1 P
+ P+ P R1 P P P
P P+ P+ P+ P P P P P
R1R2R3C R1 R2 R3 C
+ R1 R2 R3 C+
R1R2C R1 R2 C
+ C+ R1 R2 C+ C+
R1C R1 C
+ C+ C+ R1 C+ C+ C+
C C+ C+ C+ C+ C+ C+ C+ C+
R1—time from start to the first recurrence.
R2—time from start to the second recurrence.
R3—time from start to the third recurrence.
P—time from start to the progression.
+—Censoring indicator.
(k = 1), time to the second recurrence (k = 2), time to the third recurrence (k = 3) and time to the progression
(k = 4). That is to say, we suppose that each patient may experience 3 recurrences and one progression. So, if the
number of recurrences is smaller, the time of progression P will be a censored time in the stratum corresponding to
the recurrence not observed (see Table 1). For example, two recurrences followed by progression (R1R2P) will give
a time R1 in the first stratum, a time R2 in the second one, a censored time P+ in the third one, and a time P in the
fourth one. On the other hand, if there is no progression, the time C from start to the end of study will give a censored
time C+ in the stratum corresponding to the event not observed. For example, one recurrence without progression and
follow-up until time to the end of study C , will give censored times C+ in the strata k = 2, 3, 4.
Approach II defines the kth event as a subject’s kth recurrence or progression, whichever comes first (k = 1, 2, 3).
Event 4 (progression) is defined in the same manner as approach I. In this case the progression time P is the actual
event time, and it is not censored.
When events are defined as approach I, the hazard function (4) for the first three strata expresses the hazard for the
kth recurrence at time t,
λk(t) = lim
h→0
1
h
P(t ≤ Tk < t + h, ak = 1 | Tk ≥ t), k = 1, 2, 3,
where
Tk = time from start until kth recurrence or progression, whichever comes first,
and the indicator variable:
ak =
{
1, if the individual experiences at least k recurrences
2, otherwise
and for the fourth strata it expresses the hazard function for the time until progression,
λp(t) = lim
h→0
1
h
P(t ≤ Tp < t + h, |Tp ≥ t),
where
Tp = time from start until progression.
Nevertheless when events are defined as approach II, the hazard function (4) for the first three strata expresses the
hazard for the kth recurrence or progression, whichever comes first at time t. That is:
λk(t) = lim
h→0
1
h
P(t ≤ Tk < t + h|Tk ≥ t), k = 1, 2, 3
and for the fourth strata expresses the hazard function for the time until progression, λp, as in approach I.
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Fig. 2. The recurrence–progression process. Database from La Fe University Hospital of Valencia.
The way in which the two approaches with their events are defined is going to determine the meaning of the
regression parameters βk . From approach I we notice the first three events are only recurrences (superficial TCC) and
the last one is a progression. As we are clearly separating the two possible outcomes then we can discriminate and
distinguish which factors can influence in a superficial TCC and which factors can influence in a progression and thus
evaluate their effects.
3. Results
3.1. Data
The analysis has been carried out from data gathered from the Department of Urology at La Fe University Hospital
in Valencia (Spain). This database contains detailed information on superficial TCC of the bladder and was collected
from 380 post-operative patients, between January 1995 and January 2006. All patients presented a primary superficial
TCC which was removed by means of the TUR.
We will distinguish between clinical characteristics of the tumor (number of tumors and size of the tumoral
mass), and pathological characteristics (grade and stage). The stage of the bladder tumors is classified as Ta and
T1 (corresponding to superficial bladder tumors) which have a tendency for recurrence generally in tumors of similar
stage, Tis and T2–T4 (corresponding to tumors with a strong metastatized potential or progression) according to TNM
system classification [25]. Grade is categorized from G1 to G3 (from low aggressive to highly aggressive) according
to the WHO (World Health Organization) [26].
Sex and Age were collected at the moment of the TUR. Number was classified into two levels: one and two or more
tumors. Size has also two levels: minor or equal to 3 cm and more than 3 cm. The Stage variable has two categories:
Ta and T1. Only levels G1 and G2 were observed for Grade. The initial treatment for all patients consisted of a
randomized trial of 3 groups: group 1 of patients with no treatment, group 2 with a single dose of a chemotherapic 24
hours post-TUR and, group 3 with multiple instillations of a chemotherapic. Our reference individual is a man with
a mean age of 64.63 ± 12 years, with clinico-pathologic factors stage Ta and grade G1 and, only one tumor of size
minor or equal to 3 cm. He was assigned to the no-treatment group after TUR. A descriptive analysis of the patient
population and an exhaustive description of these clinico-pathological factors and the bladder tumors is carried out
in [27].
Along the follow-up period all recurrences underwent for each patient were recorded, the type of the recurrent
tumor (superficial TCC or progression) that allow us to study the recurrence–progression process. The mean follow-
up period was 1213 days (3 years and 4 months). Of the 380 patients, 178 (46.8%) underwent at least one recurrence,
84 (22%) at least two recurrences and 53 (14%) at least three recurrences in a mean time of 647.5 days (1 year and 9
months), 912.2 days (2 years and 6 months) and 1240 days (3 years and 5 months) from the TUR to the first, second
and third recurrences respectively. 24 patients (6%) underwent a progression in a mean time of 956.8 days (2 years
and 8 months). The multiple sequential tumor recurrences and progression process is depicted in Fig. 2.
The first step in applying and fitting the WLWmethod is to construct an adequate database. The procedure is shown
in Table 2. The K = 4 strata would be coded as 4 observations or “rows” of data, each one identified with the variable
enum, with the corresponding value of time and the associated indicator variable of event status. For example, let us
consider a patient A with two recurrences and a progression (R1R2P) in the days 200th, 326th and 400th, the time
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Table 2
Database to perform WLW model
Observation APPROACH I APPROACH II
Patient Time Status enum Time Status enum
A 200 1 1 200 1 1
A 326 1 2 326 1 2
A 400 0 3 400 1 3
A 400 1 4 400 1 4
B 78 1 1 78 1 1
B 189 1 2 189 1 2
B 269 1 3 269 1 3
B 269 0 4 269 0 4
C 123 0 1 123 0 1
C 123 0 2 123 0 2
C 123 0 3 123 0 3
C 123 0 4 123 0 4
variable will take the values 200, 326, 400 and 400 for each strata. The corresponding status variable will be coded
as 1,1,0 and 1 for the approach I and as 1,1,1 and 1 for the approach II. Let us suppose that another patient B has
recurrences in the days 78th, 189th and 269th without additional follow-up period (R1R2R3C). The time variable for
this patient will be coded as 78, 189, 269 and 269 with status variable values 1, 1, 1, 0 for both approaches. Only the
last observation will be censored. Finally a patient C with follow-up to day 123th but no events (C) will take the time
value 123 and status code 0 for all strata in both approaches.
In this way our data base was formed by 1520 observations (rows). Each row was completed with the observed
value of the explanatory variables sex, age, stage, grade, number of tumors, size and treatment at the starting moment.
3.2. Hypotheses of interest and contrast of the two approaches
For the analysis of this section we will go on referring to Table 1 where K = 4 strata are defined for each approach.
The way in which events are defined with the WLW method will determine the meaning of the regression parameters
βk (k = 1, 2, 3, 4) in (5). We carry out a selection of hypotheses below to compare variable categories and so to
determine which variables have more influence in a new recurrence and which variables are predictive factors in the
progression.
The hypotheses of interest will be expressed as contrasts of β1, β2, β3, β4. We use the following tests:
(1) A global hypothesis like H0 : β1 = β2 = β3 = β4 = 0 can be tested by the robust Wald statistic (βˆ ′V−1βˆ) where
V−1 is the robust variance–covariance matrix estimated for βˆ. This test has an approximate chi-square distribution
with 3 degrees of freedom.
(2) The assumption that the covariates are acting similarly on the baseline hazard function in each stratum can be
tested by using a Likelihood Ratio Test, −2[LL(β) −∑Kj=1 LL j (β j )] where LL(β) is the log partial likelihood
function assuming a common β in each stratum and LL j (β j ) is the log partial likelihood of the fitted model for
the j th stratum. This test has an approximate χ2 distribution with 3 degrees of freedom under the null hypothesis.
In our analysis the time until the first event (recurrence or progression) is of primary interest because it measures
the patient’s disease-free survival. For this purpose we can test the hypothesis β1 = 0 in approach II and it would
let us know the associated factors on the risk of a first event. In this sense the same hypothesis in approach I would
let us know the associated factors on the risk of only the first recurrence. As time until only progression is also very
important in our analysis, we assess it by testing β4 = 0 in both approaches.
3.3. Results
The first step was to fit the WLW method for each variable in the framework of both approaches. This allowed us
to detect the predictive factors associated to a recurrence and/or progression and whether their effects are equal across
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Table 3
Estimates of regression parameters for each variable
Approach I Approach II
Variables βˆ exp(βˆ) s.e. robust p βˆ exp(βˆ) s.e. robust p
Stage
βˆ 0.287 1.33 0.124 0.183 0.12 βˆ 0.431 1.54 0.12 0.185 0.02
βˆ1 (R1) 0.241 1.27 0.169 0.170 0.16 βˆ1 (R1P) 0.272 1.31 0.167 0.168 0.10
βˆ2 (R2) 0.226 1.25 0.246 0.247 0.36 βˆ2 (R2P) 0.539 1.71 0.276 0.275 0.05
βˆ3 (R3) 0.131 1.14 0.301 0.298 0.66 βˆ3 (R3P) 0.027 1.03 0.011 0.010 0.01
βˆ4 (P) 1.647 5.19 0.737 0.739 0.02 βˆ4 (P) 1.647 5.19 0.737 0.739 0.02
Grade
βˆ 0.699 2.01 0.112 0.163 0.00 βˆ 0.861 2.36 0.106 0.165 0.00
βˆ1 (R1) 0.604 1.83 0.153 0.152 0.00 βˆ1 (R1P) 0.654 1.92 0.151 0.150 0.00
βˆ2 (R2) 0.575 1.78 0.223 0.221 0.00 βˆ2 (R2P) 0.822 2.27 0.206 0.205 0.00
βˆ3 (R3) 0.714 2.04 0.280 0.274 0.00 βˆ3 (R3P) 1.119 3.06 0.246 0.243 0.00
βˆ4 (P) 2.200 9.03 0.619 0.627 0.00 βˆ4 (P) 2.200 9.03 0.619 0.627 0.00
Number
βˆ 0.822 2.27 0.131 0.194 0.00 βˆ 0.748 2.11 0.124 0.199 0.00
βˆ1 (R1) 0.827 2.29 0.188 0.190 0.00 βˆ1 (R1P) 0.801 2.23 0.185 0.188 0.00
βˆ2 (R2) 0.921 2.51 0.253 0.242 0.00 βˆ2 (R2P) 0.799 2.22 0.234 0.229 0.00
βˆ3 (R3) 0.913 2.49 0.307 0.308 0.000 βˆ3 (R3P) 0.737 2.09 0.267 0.270 0.00
βˆ4 (P) 0.169 1.18 0.552 0.566 0.76 βˆ4 (P) 0.169 1.18 0.552 0.566 0.76
Size
βˆ 0.722 2.06 0.119 0.182 0.00 βˆ 0.602 1.83 0.114 0.182 0.00
βˆ1 (R1) 0.652 1.919 0.168 0.178 0.00 βˆ1 (R1P) 0.616 1.852 0.166 0.174 0.00
βˆ2 (R2) 0.940 2.561 0.231 0.237 0.00 βˆ2 (R2P) 0.734 2.084 0.217 0.220 0.00
βˆ3 (R3) 1.056 2.874 0.285 0.284 0.00 βˆ3 (R3P) 0.695 2.003 0.250 0.245 0.00
βˆ4 (P) −0.602 0.548 0.618 0.606 0.3 βˆ4 (P) −0.602 0.548 0.618 0.606 0.32
Sex
βˆ 0.126 1.13 0.145 0.200 0.51 βˆ 0.046 1.05 0.14 0.204 0.82
βˆ1 (R1) 0.202 1.22 0.198 0.200 0.31 βˆ1 (R1P) 0.150 1.16 0.197 0.199 0.45
βˆ2 (R2) 0.195 1.22 0.285 0.267 0.46 βˆ2 (R2P) 0.109 1.12 0.266 0.247 0.66
βˆ3 (R3) 0.014 1.01 0.367 0.330 0.97 βˆ3 (R3P) −0.139 0.87 0.327 0.300 0.64
βˆ4 (P) −0.628 0.53 0.738 0.737 0.39 βˆ4 (P) −0.629 0.53 0.738 0.737 0.39
Age
βˆ 0.014 1.01 0.005 0.007 0.05 βˆ 0.019 1.02 0.005 0.007 0.01
βˆ1 (R1) 0.012 1.01 0.007 0.007 0.08 βˆ1 (R1P) 0.013 1.01 0.007 0.007 0.05
βˆ2 (R2) 0.004 1.00 0.009 0.008 0.62 βˆ2 (R2P) 0.015 1.02 0.009 0.008 0.07
βˆ3 (R3) 0.002 1.01 0.012 0.011 0.36 βˆ3 (R3P) 0.027 1.03 0.011 0.010 0.01
βˆ4 (P) 0.076 1.08 0.022 0.018 0.00 βˆ4 (P) 0.076 1.08 0.022 0.018 0.00
all strata. For each approach, Table 3 gives the estimated values of different effects (βˆ1, βˆ2, βˆ3, βˆ4) and the estimated
common value βˆ.
Testing the hypothesis H0 : β4 = 0 in both approaches we can see that stage T1 increases the risk of progression
with respect to the stage Ta, however testing H0 : β j = 0 j = 1, 2, 3 in approach I we see that the increase of
risk of recurrence is not significant. The other pathological variable indicates that level G2 increases the risk for both
recurrence and progression with respect to level G1. Moreover the highest increase is on progression. This different
effect may be seen in tests 1 and 5 of Table 4. The estimated βk for the clinical variables number and size reflects a
significant effect on the recurrence but not on progression. Test 3 for number and size shows a common effect across
the recurrence strata. However age presents a different effect between recurrence and progression (test 1). Finally sex
did not show any significant effect. From the obtained results of both tables we can conclude that the pathological
variables (stage and grade) have influence on progression and recurrence whereas the clinical variables (number and
size) only have influence on recurrence.
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Table 4
Results of tests of hypotheses
Test Hypothesis Approach I Approach II
T1 T2 T1 T2
Stage
1 β1 = β2 = β3 = β4 – 0.15 – 0.18
2 β1 = β2 = β3 = β4 = 0 0.03 0.15 0.00 0.14
3 β1 = β2 = β3 – 0.95 – 0.65
4 β1 = β2 = β3 = 0 0.37 0.52 0.01 0.23
5 β1 = β4 0.06 – 0.07 –
Grade
1 β1 = β2 = β3 = β4 – 0.03 – 0.02
2 β1 = β2 = β3 = β4 = 0 0.00 0.00 0.00 0.00
3 β1 = β2 = β3 – 0.92 – 0.26
4 β1 = β2 = β3 = 0 0.00 0.00 0.00 0.00
5 β1 = β4 0.01 – 0.02 –
Number
1 β1 = β2 = β3 = β4 – 0.60 – 0.71
2 β1 = β2 = β3 = β4 = 0 0.00 0.00 0.00 0.00
3 β1 = β2 = β3 – 0.94 – 0.97
4 β1 = β2 = β3 = 0 0.00 0.00 0.00 0.00
5 β1 = β4 0.27 – 0.27 –
Size
1 β1 = β2 = β3 = β4 – 0.13 – 0.15
2 β1 = β2 = β3 = β4 = 0 0.00 0.00 0.00 0.00
3 β1 = β2 = β3 – 0.38 – 0.90
4 β1 = β2 = β3 = 0 0.00 0.00 0.00 0.00
5 β1 = β4 0.047 – 0.05 –
Sex
1 β1 = β2 = β3 = β4 – 0.66 – 0.64
2 β1 = β2 = β3 = β4 = 0 0.67 0.64 0.78 0.68
3 β1 = β2 = β3 – 0.88 – 0.74
4 β1 = β2 = β3 = 0 0.69 0.69 0.82 0.60
5 β1 = β4 0.28 – 0.31 –
Age
1 β1 = β2 = β3 = β4 – 0.02 – 0.03
2 β1 = β2 = β3 = β4 = 0 0.00 0.00 0.00 0.00
3 β1 = β2 = β3 – 0.81 – 0.55
4 β1 = β2 = β3 = 0 0.24 0.23 0.00 0.045
5 β1 = β4 0.00 – 0.00 –
Now the following step is to perform a predictive model for the occurrence of an event and in this way we would
be able to know the associated factors to the disease-free time. The results of this analysis are very interesting from a
medical point of view. For this purpose we focus on approach II with a multivariate analysis. We use the Likelihood
Ratio test to determine which combination of explanatory variables has an influence on the occurrence of an event.
We obtained sex, size, grade and number as predictive factors. For studying the effect of the treatment, we define two
indicator or dummy variables for the three levels of the treatment variable. Including these variables, the value of the
statistic −2 log Lˆ is reduced to 44.63 on 2 degrees of freedom, statistically significant at the 1% level. Table 5 shows
the parameter estimates and the robust standard errors.
Some conclusions from the parameter estimates are the following. When age is increased by one year, the risk
of recurrence or progression is increased by 2%. Patients with size tumor greater than 3 cm have an 82% risk of
recurrence or progression higher than patients with size tumor smaller than 3 cm. Patients with tumor grade G2
have a 2.2-fold increased risk of recurrence or progression than patients with tumor grade G1. Patients with multiple
tumors have a risk increase 2.24-fold with respect to patients with a single tumor. Finally, multiple instillations of a
chemotherapic is the most effective treatment.
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Table 5
WLW parameter estimates
Variables βˆ exp(βˆ) s.e. robust s.e. p
Age 0.019 1.02 0.005 0.007 0.00
Size 0.599 1.82 0.128 0.202 0.00
Grade 0.798 2.22 0.109 0.168 0.00
Number 0.804 2.24 0.129 0.201 0.00
Treat1 0.255 1.29 0.167 0.262 0.33
Treat2 −0.654 0.52 0.143 0.214 0.00
(treat1: single dose; treat2: multiple instillations).
Fig. 3. Plots of Scaled Schoenfeld residuals against time for each variable.
3.4. Validation
The WLW method assumes proportional hazards, that is, with time-fixed covariates, the relative hazard for any
two subjects inside the same strata is independent of time. Assessment of the proportional hazards assumption for
each variable effect estimate uses a test and graphical diagnostic based on the scaled Schoenfeld residuals s∗t . In [16]
it is shown that the expected value of this residual at time t for event k is given by E(s∗t ) ≈ βˆk(t) − βˆk , and so a
plot of the values of s∗t + βˆk against time will give information about the funcional form of βk(t). Fig. 3 indicates no
suggestion of non-proportional hazards and that the coefficients of these variables are constant. The interpretation of
this graphical diagnostic is greatly facilitated by the smoothing shown on each one with a solid line.
In order to validate the fitted model we carry out two activities: discrimination and calibration. In the first place,
discrimination was quantified with the concordance index c [28] which is the non-parametric version of the area
under the receiver operating characteristic curve (ROC) and applicable to time-until-event data. On a 0.5 to 1.0 scale
c provides the probability that, in a randomly selected pair of patients in which one patient recurrences before the
other, the patient who recurred first had the worse predicted outcome from the model. c = 0.5 represents agreement
by chance; c = 1.0 represents perfect discrimination [29]. A total of 200 bootstrapping resamples were used to reduce
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Fig. 4. Calibration plot for prediction of disease-free at 1 year.
overfit bias and for internal validation [30,31]. The bootstrap-corrected concordance index c for predicting one year
disease-free survival for our model was 0.78.
Secondly, calibration was done by grouping patients with respect to their model-predicted probabilities and then
comparing the mean of the group with the observed Kaplan–Meier [32] estimate of disease-specific survival. In Fig. 4,
points (◦) correspond with predictions from the model for a subcohort containing a fifth of the total cohort. Note that
these points are close to the dotted line, what indicates that predictions fit well to observed results. Crosses (×)
indicate the corrected probabilities by means of bootstrapping [28]. All of them are very close, what indicates a good
fit.
We have performed a post-operative nomogram [28] from the fitted model because sometimes it arises in the clinic
practice the need for getting together the information in a simple and graphic tool. The nomogram depicted in Fig. 5
will help the physician to decide the treatment and protocol of follow-up more suitable for each patient. We have not
included treatment because the aim was to provide a graphical tool for the clinician and patient to decide the most
suitable treatment to the situation of his (her) disease. However, we have also internally validated the model without
treatment and the concordance index obtained (c = 0.76) was similar to the preceding model.
4. Conclusions and remarks
In our analysis we have considered a maximum of 3 recurrences per subject, but some patients had 4 or more
recurrences, and thus we could have taken K = 5 and defined the two considered approaches analogous to the
definition in Table 1 but choosing K too large can be problematic because there are too few recurrences and
progressions to estimate βk for certain k. In fact the average number of recurrences per patient is 1.2.
The applied methodology has allowed us to distinguish between two different types of events: recurrence and
progression. In this way we have been able to detect the different effects of the predictive factors on both events. The
most remarkable conclusion was that among pathological factors only stage presented a clearly significant effect on
the progression, meanwhile grade resulted highly significant for both events. The clinical factors (number and size)
did not show any significant effect on progression but they were significant factors on recurrence.
We have obtained a model that predicts the risk of recurrence or progression along time, depending on age, grade,
number, size and treatment. The concordance index of the model corresponding to a year is 0.78. Predictive models
for prostate cancer based on standard clinical factors like ours present concordance indexes in a rank from 0.65 to
0.72 [33–35]. In a recent work [36] this value rises to 0.83, but incorporates two new molecular markers, what is not
so easily applicable to clinical practice like models with standard factors alone. In [27] a predictive model is presented
based on standard factors for bladder cancer recurrence whose concordance index was 0.65.
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Fig. 5. Nomogram for predicting 1 year disease survival. To read nomogram draw vertical line from each tick mark indicating predictor status to
top axis (Points). Calculate total points and find corresponding number on axis (Total Points). Draw vertical lines down to axes showing 1 year
disease-free probability for type of event in approach II.
The obtained model is based only on standard clinico-pathological factors, and thus it is meant to be a tool available
to any hospital. Nowadays, the follow-up and treatment is the same for all superficial tumors. With this model, we try
to individualize the course of follow-up and treatment of each patient in order to improve the patient’s quality of life.
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